Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 11/20 | 0.63 |
| ▸ | DRD2 | P14416 | 11/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801779 | 0.91 | SLC6A4 (0.70) | SLC6A4HTR1ADRD2KDM4EMEN1 | |
| SCHEMBL6811482 | 0.86 | SLC6A4 (0.64) | SLC6A4HTR1ADRD2KDM4EMEN1 | |
| SCHEMBL4697961 | 0.85 | SLC6A4 (0.67) | SLC6A4HTR1ADRD2KDM4EMEN1 | |
| SCHEMBL3233304 | 0.83 | SLC6A4 (0.67) | SLC6A4HTR1ADRD2MAPTHTR2C | |
| SCHEMBL1232327 | 0.83 | SLC6A4 (0.50) | SLC6A4MAPT | |
| SCHEMBL1703585 | 0.83 | SLC6A4 (0.67) | SLC6A4HTR1ADRD2MAPTHTR6 | |
| SCHEMBL7704740 | 0.82 | SLC6A4 (1.00) | SLC6A4HTR1ADRD2 | |
| Oxalic Acid SCHEMBL8869051 | 0.80 | SLC6A4 (0.77) | SLC6A4HTR1ADRD2 | |
| SCHEMBL6345407 | 0.80 | SLC6A4 (0.69) | SLC6A4HTR1AHTR6 | |
| SCHEMBL18324680 | 0.80 | SLC6A4 (0.70) | SLC6A4HTR1ADRD2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | claimed |
| EP-1902044-A1 | 5-HTX MODULATORS | Bio Medisinsk Innovasjon AS (NO) | 2008-03-26 | — | — | EP | claimed |
| WO-2007007072-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2007-01-18 | — | — | WO | claimed |
| CN-106045967-B | Substituted heterocyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-106045966-B | Substituted heterocyclic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| EP-1560823-B1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1560823-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043949-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | SLC6A4 20/4885HTR1A 4/4885DRD2 75/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | SLC6A4 1958/4885HTR1A 264/4885DRD2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.